Developments in breast cancer biology over the last years have permitted deconstructing the molecular profile of the most relevant breast cancer subtypes. This has led to an increase in therapeutic options, including more effective personalized therapy for breast cancer and substantial improvements in patient outcomes. Although currently there are only a few targeted therapies approved for metastatic breast cancer, the discovery of druggable kinase gene alterations has radically changed cancer treatment by providing novel and successfully actionable drug targets. Fibroblast growth factors and their receptors (FGFRs) participate in different physiologic processes and also play an essential role in cancer cell proliferation, survival, differentiation, migration, and apoptosis. This article summarizes the main molecular alterations of FGFRs, as well as the available preclinical and clinical data with FGFR inhibitors in breast cancer, and discusses new opportunities for the clinical development of these agents in patients with breast cancer.
Introduction
Breast cancer is a heterogeneous disease with multiple clinical presentations and tumor characteristics. In recent years, gene expression profiling studies have classified breast tumors into four different molecular subtypes (luminal A, luminal B, HER2 enriched, and basal-like), leading to a new classification of breast cancer with prognostic and therapeutic implications [1] .
Developments in breast cancer biology over the last years have permitted deconstructing the molecular profile of the most relevant breast cancer subtypes. This has led to an increase in therapeutic options, including more effective personalized therapy for breast cancer and substantial improvements in patient outcomes [2] . To date, the US Food and Drug Administration (FDA) has only approved a limited number of targeted therapies for the treatment of breast cancer. In addition to endocrine therapy, these include: five anti-HER2 therapies (trastuzumab, lapatinib, neratinib, and pertuzumab), everolimus, palbociclib, ribociclib, and abemaciclib [3e12] . However, other strategies targeting different tyrosine kinase receptors are currently under way.
The fibroblast growth factor receptor (FGFR) family comprises five transmembrane receptors, all but one with tyrosine kinase activity. During the past few years, considerable research has confirmed the essential role of FGFR signaling in cancer cell proliferation, angiogenesis, and survival, and this pathway appears, therefore, to be an excellent target for cancer therapy [13] .
In this review, we summarize the main molecular alterations of FGFRs, as well as the available preclinical and clinical data with FGFR inhibitors in breast cancer, and discuss new opportunities for the clinical development of these agents in patients with breast cancer.
The fibroblast growth factor (FGF)/FGFR signaling pathway
FGFs and FGFRs are involved in different physiologic processes, such as embryonic development, regulation of angiogenesis, and wound repair, among others. Additionally, the FGF/FGFR signaling network plays a critical role in cancer cell proliferation, survival, differentiation, migration, and apoptosis. For these reasons, dysregulation of the FGF/FGFR pathway consistently has been associated with human cancers as well as many other developmental disorders [13, 14] .
The human FGFR family contains four classical FGFRs (FGFR1, FGFR2, FGFR3, and FGFR4) encoded by four distinct genes (FGFR1-4). It is noteworthy to mention that in addition to the classical receptors encoded by FGFR genes, several isoforms with different ligand-binding affinities are generated through alternative splicing of FGFR1 through FGFR3. Each receptor comprises an extracellular domain, a transmembrane domain, and a tyrosine kinase cytoplasmic domain. The extracellular region consists of three immunoglobulin-like (Ig) domains (IgI, IgII, and IgIII) and an acid box, typically located between IgI and IgII. The IgII and IgIII domains constitute the FGF ligand-binding site [15] . Recently, a fifth member of the FGFR family has been discovered, the fibroblast growth factor receptor like 1 (FGFRL1 or FGFR5) , that also contains three extracellular Ig-like domains but lacks the protein tyrosine kinase domain [16] .
The FGF family of ligands comprises 18 members (FGF1eFGF10 and FGF16eFGF23) that may be categorized into two groups. The first consists of hormone-like FGFs (FGF19, FGF21, and FGF23) that function in an endocrine manner and can bind to FGFRs through the presence of klotho proteins. The second contains the canonical FGFs (FGF1eFGF10, FGF16eFGF18, FGF20, and FGF22) that are captured in the cell surface or in the extracellular matrix by heparan sulfate glycosaminoglycans and act as paracrine or autocrine growth factors.
Binding of FGFs to FGFRs leads to receptor dimerization, resulting in the transphosphorylation of a tyrosine in the activation loop of the kinase domain. Subsequently, the activated FGFRs phosphorylate their intracellular receptor substrates, particularly FGFR substrate 2 (FRS2) and phospholipase Cg (PLCg). On one hand, activated FRS2 promotes downstream signaling through the RASemitogen-activated protein kinase (MAPK) or the phosphoinositide 3-kinase (PI3K)eAKT pathways that regulate cell proliferation, differentiation, and survival. On the other hand, the activation of PLCg leads to the release of calcium ions from the intracellular compartment and to the activation of calciumdependent signaling, events that mediate cell motility. Moreover, there are other effector proteins activated by FGFRs, such as Signal Transducers and Activators of Transcription (STAT) factors, Src, and RAF, through the stimulation of protein kinase C (Fig. 1) [17] .
Nevertheless, the regulatory mechanisms involved in the control of FGFR signaling are poorly understood and likely are different depending on tumor type and molecular context. Therefore, additional research in this area is warranted.
Genomic aberrations of the FGF/FGFR signaling pathway in breast cancer
The FGF/FGFR signaling pathway is frequently deregulated in human cancers. Overall, FGFR alterations have been found in 7.1% of cancers, with the majority being gene amplifications (66% of the aberrations), followed by mutations (26%) and rearrangements (8%) [18] . Tumor types most commonly affected are urothelial (32% FGFR-aberrant), breast (18%), endometrial (~13%), squamous lung cancers (~13%), and ovarian cancer (~9%). Moreover, liganddependent mechanisms are also responsible of the aberrant activation of FGFR signaling through the paracrine and/or autocrine production of FGFs proteins by stromal and/or tumor cells.
In breast cancer, FGFR1 amplification represents the most frequent genomic aberration, whereas amplification of FGFR2e4 genes and FGFR activating mutations are uncommon. These alterations are discussed further in the following sections (Table 1) .
FGFR1 gene amplification
The 8p11-12 chromosomal region harboring the FGFR1 gene locus is amplified in about 14% of breast cancer patients, with a range from 8.7% to 23% depending on the study, principally in the hormone receptor (HR)-positive/HER2-negative subtype [18e20]. It is important to highlight that genes other than FGFR1 within the 8p11-12 amplicon also may promote breast cancer development. Furthermore, in up to one third of patients, the FGFR1 gene is amplified simultaneously with an amplicon on chromosome 11q12-14 that contains additional oncogenes, such as CCND1, FGF3, FGF4, and FGF19 [21, 22] . However, in vitro studies have demonstrated that FGFR1 expression by itself is required for the survival of FGFR1-amplified breast cancer cell lines, supporting the oncogenic potential of FGFR1 amplification [23].
FGFR2 gene amplification
The FGFR2 gene located on chromosome 10q26 is amplified in approximately 4% of triple-negative breast cancers but appears to be a relatively rare event in other tumor subtypes, occurring in less than 1% of all breast cancers [18, 24] . In contrast to FGFR1 amplification, the presence of other important oncogenes in this amplicon is less relevant, and its coamplification with other chromosomal regions has not been reported. Nevertheless, breast cancer cell lines with high levels of amplification of FGFR2 are also highly sensitive to FGFR inhibitors, indicating that FGFR2 amplification could signify addiction to the FGFR pathway for growth [25] .
FGFR3 and FGFR4 genes amplification
Amplification of the FGFR3 and FGFR4 genes has been detected in less than 1% and around 2.3% of breast cancer patients, respectively [18] However, another study has revealed the presence of increased FGFR4 mRNA levels in up to 30% of patients with breast cancer, suggesting a discrepancy between FGFR amplification and FGFR mRNA levels that will be further discussed in the manuscript in more detail [26] .
FGFR mutations and fusions
Although FGFR mutations are common in other tumor types, such as endometrial (FGFR2) and urothelial cancers (FGFR3), their incidence is much lower in breast cancer [18] . However, FGFR mutations with unknown functional significance have also been identified in human breast cancers [27] . Moreover, the use of new tools for genome analysis has recently allowed the identification of FGFR1 and FGFR2 gene fusions with oncogenic potential in four breast cancer patients [28] . This implies that the implementation of next-generation sequencing (NGS) technologies will be critical for the detection of novel druggable oncogenic alterations in the coming years.
Role of the FGF/FGFR signaling pathway in the treatment of breast cancer
Preclinical data have consistently shown that FGFR1-and FGFR2-amplified breast cancer cell lines and xenografts are more sensitive than nonamplified models to growth inhibition by FGFR inhibitors [29, 30] . Moreover, alterations in the FGF/FGFR signaling pathway may also have important clinical implications in breast cancer patients.
Despite the fact that the role of FGFR2 amplification in the management of breast cancer remains unclear, several studies have confirmed the clinical and biological importance of FGFR1
